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Introduction: Treatments for type 2 diabetes targeting baseline glucose levels but not
postprandial glucose can result in normalized fasting blood glucose but suboptimal overall
glycemic control (high glycated hemoglobin): residual hyperglycemia. In Japanese patients
with type 2 diabetes the predominant pathophysiology is a lower insulin secretory capac-
ity, and residual hyperglycemia is common with basal insulin treatment. Single-injection,
fixed-ratio combinations of glucagon-like peptide-1 receptor agonists and basal insulin
have been developed. iGlarLixi (insulin glargine 100 units/mL [iGlar]: lixisenatide ratio of 1
unit:1 µg) is for specific use in Japan. Post-hoc analysis of the LixiLan JP-L trial
(NCT02752412) compared the effect of iGlarLixi with iGlar on this specific subpopulation
with residual hyperglycemia.
Materials and Methods: Outcomes at week 26 (based on the last observation carried
forward) were assessed in patients in the modified intent-to-treat population with baseline
residual hyperglycemia.
Results: Overall, 83 (32.5%) patients in the iGlarLixi group and 79 (30.7%) patients in the
iGlar group had baseline residual hyperglycemia. The proportion of patients with residual
hyperglycemia at week 26 decreased to 15.7% in the iGlarLixi group, and increased to
36.9% in the iGlar group. Patients in the iGlarLixi group had significantly greater reductions
in glycated hemoglobin compared with the iGlar group (-0.72% difference between
groups; P < 0.0001).
Conclusions: New data from this post-hoc analysis of the JP-L trial show that treatment
with the fixed-ratio combination iGlarLixi reduced the proportion of Japanese patients
with residual hyperglycemia from baseline to week 26 and significantly reduced glycated
hemoglobin vs similar doses of iGlar alone.
INTRODUCTION
Overall glycemic control in patients with type 2 diabetes is cur-
rently evaluated based on a glycated hemoglobin (HbA1c) tar-
get1. HbA1c reflects the dynamics of both fasting plasma
glucose (FPG) and postprandial plasma glucose (PPG) and, as
such, acts as an index of overall glycemic load. The widely
adopted use of basal insulin in the treatment of type 2 diabetes
is based on the titration of the basal insulin dose to achieve a
target FPG1,2. The control of FPG may be sufficient to achieve
a level of overall glycemic control that delivers an optimal
HbA1c in a significant number of patients3. However, PPG
continues to contribute to the overall glycemic load in many
patients, and this can manifest as a failure to achieve target
HbA1c despite having achieved FPG control. In many patientsReceived 5 August 2020; revised 26 March 2021; accepted 18 April 2021
1992 J Diabetes Investig Vol. 12 No. 11 November 2021 ª 2021 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
ORIGINAL ARTICLE
with type 2 diabetes, adequate control of PPG is essential for
achieving the recommended HbA1c goals4.
It is well recognized that as HbA1c levels approach 7% there
is an increase in the relative contribution of PPG to HbA1c4–6.
This dynamic means that many patients on basal insulin fail to
achieve HbA1c <7% as a consequence of persistent postpran-
dial hyperglycemia, despite achieving FPG control. This has
been described as residual hyperglycemia, and is defined as
HbA1c ≥7% with FPG <130 mg/dL for Asian and Latin Amer-
ican countries (according to regional specifications) or
<140 mg/dL for the rest of the world7–9.
An analysis combining data from randomized controlled
clinical trials, clinical trial registries, and medical records across
the world found that substantial proportions of patients with
type 2 diabetes treated with basal insulin had residual hyper-
glycemia (28–36%)9. The relative importance of PPG appears
to differ between patient groups and may be dependent on the
pathophysiology of the disease. PPG control has particular sig-
nificance in East Asians with type 2 diabetes because of the
prominence of b-cell dysfunction and reduced insulin secretion
compared with Caucasians, who are characterized by increased
insulin resistance and obesity10,11. A study using continuous
glucose monitoring in drug-naive Japanese patients with type 2
diabetes demonstrated a positive correlation between HbA1c
values and the range of postprandial increases after breakfast
and dinner; furthermore, peak PPG levels were higher in
patients with a ‘high’ median HbA1c (8.8%) than in patients
with a ‘low’ median HbA1c (6.8%)12.
The importance of PPG as a therapeutic target is well recog-
nized in Japan; dipeptidyl peptidase-4 (DPP-4) inhibitors are
the most frequently prescribed oral anti-diabetes drugs
(OAD)13,14 and the first-line drug of choice13,15,16. In Japan,
44–57% of patients with type 2 diabetes are on DPP-4 inhibi-
tors while only 11–17% are on biguanides13,16. This is in
marked contrast to the UK, Europe, and the USA, where guid-
ance and clinical practice identify the biguanide metformin as
the initial OAD of choice, often initiated at the point of diagno-
sis1,17.
East Asians, including the Japanese, seem to be very sensitive
to incretin therapies, e.g., DPP-4 inhibitors18, possibly due to
the unique pathophysiology of East Asians’ type 2 diabetes pri-
marily characterized by impaired b-cell function rather than
insulin resistance11,19. However, treatment with DPP-4 inhibi-
tors is insufficient for some patients to achieve or maintain gly-
cemic control20,21. These patients may require treatment
escalation, which has been traditionally either monotherapy
with basal insulin or a glucagon-like peptide-1 receptor agonist
(GLP-1 RA). However, real-world evidence suggests that these
agents alone are relatively ineffective at bringing patients to tar-
get, with only 38% of patients on basal insulin and 21%
patients on a GLP-1 RA achieving HbA1c <7% within
1 year22,23.
Recent guidance (American Diabetes Association/European
Association for the Study of Diabetes) has suggested that the
combination of insulin and a GLP-1 RA should be considered
as initial therapy in patients with HbA1c >10 or 2% above tar-
get, or in patients not achieving target with a single injectable
agent1.
A fixed-ratio combination (FRC) of a GLP-1 RA with basal
insulin has been gaining much attention recently. FRC offers
an incretin-based intervention to enhance insulin secretion and
to lower PPG levels, combined with insulin that primarily
reduces FPG. In Japan, IDegLira, a formula of an insulin deglu-
dec:liraglutide ratio of 1 unit (U) insulin degludec and
0.036 mg liraglutide, which is the same ratio as that approved
in the USA and EU24,25, is available. However, optimal basal
insulin doses for Japanese patients with type 2 diabetes may be
lower than those for Caucasians11. Therefore, an FRC of insulin
glargine 100 U/mL (iGlar) and lixisenatide (Lixi) has been
developed in Japan at a unique ratio of 1 U:1 µg (20 lg Lixi
with 20 U iGlar 100 U/mL) to allow effective GLP-1 RA dosing
with basal insulin doses appropriate for Japanese patients with
type 2 diabetes.
In phase 3 trials in Japanese patients with type 2 diabetes,
iGlarLixi with a ratio of 1 U iGlar:1 µg Lixi demonstrated sig-
nificantly greater reductions in HbA1c than those observed
with either Lixi (LixiLan JP-O1 trial)26 or iGlar (LixiLan JP-O2
and JP-L trials)27,28. As treatment with a GLP-1 RA can
improve postprandial hyperglycemia and thereby residual
hyperglycemia and HbA1c, this post-hoc analysis of the LixiLan
JP-L trial adds to the findings of the original study by compar-
ing the effect of iGlarLixi with iGlar on the specific subpopula-
tion of Japanese patients with type 2 diabetes who experienced
residual hyperglycemia.
METHODS
LixiLan JP-L trial design and post-hoc analysis
The design of LixiLan JP-L (NCT02752412), a randomized,
open-label, multicenter trial of iGlarLixi vs iGlar in Japanese
patients with type 2 diabetes uncontrolled on basal insulin and
OADs, has been described previously27. In summary, Japanese
adult patients who had been diagnosed with type 2 diabetes for
>1 year and had HbA1c ≥7.5% and ≤9.5% despite using basal
insulin and one or two OADs entered an initial 12-week run-
in period where all OADs except metformin were discontinued,
metformin therapy was initiated if not already being adminis-
tered, and existing treatment with basal insulin was continued
or switched to iGlar and optimized to reach fasting self-
monitored plasma glucose (SMPG) levels ≤160 mg/dL. At the
end of the run-in period, patients with average doses of iGlar
5–14 U/day, metformin ≥750 mg/day, and no signs of pancre-
atic disease were randomly assigned to iGlarLixi or iGlar for a
26-week treatment period. iGlarLixi was administered before
breakfast. iGlar was administered before breakfast or at bedtime
(at about the same time every day), in line with the summary
of product characteristics29 for iGlar, and as part of the agreed
protocol for the main study on which the post-hoc analysis was
based. The study was approved by the appropriate institutional
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review board at each study center and was carried out in accor-
dance with the Declaration of Helsinki and Good Clinical Prac-
tice. Written informed consent was provided in advance by all
participants.
This post-hoc analysis assessed outcomes at week 26 in
patients with residual hyperglycemia at baseline, including the
variables of weight, HbA1c, FPG, 2-h PPG (during a standard-
ized meal test), change in 7-point SMPG, and the daily dose of
iGlar. PPG and plasma glucose excursions were assessed during
a standardized meal test. Glycemic control categories were
adapted from Raccah et al.30: hyperglycemia: HbA1c ≥7% and
FPG ≥130 mg/dL; residual hyperglycemia: HbA1c ≥7% and
FPG <130 mg/dL; and HbA1c at target: HbA1c <7% and FPG
<130 mg/dL or ≥130 mg/dL. The proportion of patients in
each glycemic category (hyperglycemia, residual hyperglycemia,
and HbA1c at target) at baseline and other time points
throughout the treatment period was assessed for each treat-
ment arm.
Statistical methods
All statistical tests were performed for descriptive purposes
only; P values were without multiplicity adjustment and should
be considered nominal. Post-hoc analyses were based upon the
modified intent-to-treat (mITT) population, defined as all ran-
domized patients who received at least one dose of study treat-
ment and had both a baseline assessment and at least one
post-baseline assessment of any primary or secondary efficacy
variables. Week 26 data were based on the last available post-
baseline measurements (last observation carried forward
[LOCF]). The least squares (LS) mean difference between the
groups and corresponding standard error (SE) and 95% confi-
dence interval (CI) for the efficacy variables were estimated
using analysis of covariance with treatment groups, randomiza-
tion strata of HbA1c (<8 and ≥8%) at the end of the run-in
period and randomization strata of metformin use at screening
as fixed effects, and baseline value as a covariate. Documented
symptomatic hypoglycemia (plasma glucose <70 mg/dL) was
compared between the groups using the Cochran–Mantel–
Haenszel method stratified by randomization strata of HbA1c
(<8 and ≥8%) at the end of the run-in period and randomiza-
tion strata of metformin use at screening.
RESULTS
Patient disposition and baseline characteristics
All randomized patients qualified for the mITT population. Of
the 255 patients randomized to iGlarLixi and the 257 random-
ized to iGlar (the overall study populations), similar proportions
in the two treatment groups had residual hyperglycemia at
baseline (iGlarLixi, n = 83 [32.5%] and iGlar, n = 79 [30.7%])
(Figure 1). Among patients with baseline residual hyper-
glycemia, baseline characteristics between the treatment groups
were similar with the exception of metformin use at screening,
which was higher in the iGlarLixi group than in the iGlar
group (83.1 vs 70.9%) (Table 1). The body mass index (BMI;
kg/m2) of patients with residual hyperglycemia was numerically
lower than that of patients in the overall study population
(mean [standard deviation]; 23.49 [3.47] vs 25.32 [4.18] for
iGlarLixi; 23.78 [4.13] vs 24.88 [3.85] for iGlar).
Residual hyperglycemia over 26 weeks
In the overall study population, the proportion of patients with
residual hyperglycemia at week 26 (LOCF) decreased to 15.7%
in the iGlarLixi group and increased to 36.9% in the iGlar
group, while the proportion of patients with hyperglycemia
decreased to 32.3% and 47.1%, respectively (Figure 1). The pro-
portion of patients with HbA1c at target increased from 0.0%
in both groups at baseline to 52.0 and 16.1%, respectively, at
week 26 (LOCF). In the iGlarLixi group, there was a decrease
after week 8 of treatment, and the proportion appeared to be
stable from week 20 (Figure 2). In the iGlar group, the propor-
tion increased at week 8 and remained higher than in the
iGlarLixi group through to the end of treatment (Figure 2). Of
the original 83 patients in the iGlarLixi group who had residual
hyperglycemia at baseline, 15 (18.1%) had residual hyper-
glycemia at week 26 (LOCF); of the 79 patients in the iGlar
group, 42 (53.2%) still had residual hyperglycemia at week 26
(LOCF) (Table 2).
Weight, glycemic parameters, and insulin dose over 26 weeks
in patients with residual hyperglycemia at baseline
At week 26, iGlarLixi treatment in patients with residual hyper-
glycemia resulted in significantly greater reductions in HbA1c,
body weight, and 2-h PPG when compared with iGlar treat-
ment (Table 3). The HbA1c change (SD) was –1.17% (0.87%)
and –0.44% (0.73%) in the iGlarLixi and iGlar arms, respec-
tively (LS mean difference [SE] –0.72% [0.128]; P < 0.0001).
The mean change (SD) in body weight among patients taking
iGlarLixi was -0.40 (2.17) kg vs an increase of 0.57 (1.69) kg
in those taking iGlar (LS mean difference [SE] –0.97 [0.317] kg;
P = 0.0025). The mean (SD) 2-h PPG changes were -111.19
(71.34) mg/dL among patients taking iGlarLixi and -23.54
(55.32) mg/dL among patients taking iGlar (LS mean difference
[SE] -90.65 (9.110) mg/dL; P < 0.0001).
The FPG increased in both treatment groups. Although the
increase was higher in the iGlarLixi group, the difference
between the groups was not statistically significant (Table 3).
The mean (SD) FPG at baseline increased by 14.93 (41.92) mg/
dL to 122.96 (38.74) mg/dL at week 26 (LOCF) for patients
who received iGlarLixi, and by 6.35 (30.46) mg/dL to 115.67
(28.12) mg/dL at week 26 (LOCF) for patients who received
iGlar (LS mean difference for change [SE] 7.33 [5.485] mg/dL;
P = 0.1834). iGlarLixi demonstrated lower mean values than
iGlar for 7-point SMPG profiles across all time points except
pre-breakfast (Figure S1).
There was no significant difference between the iGlarLixi
and iGlar groups in the change of average daily dose of insulin
from baseline to week 26 (LS mean difference [SE] -0.51
[0.565]; P = 0.3640).
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No significant differences were seen in the proportion of
patients experiencing documented symptomatic hypoglycemia,
defined as a plasma glucose of <70 mg/dL (22.9% and 25.3%
of patients in the iGlarLixi and iGlar arms, respectively).
DISCUSSION
This post-hoc analysis of the LixiLan JP-L trial demonstrated
that following a run-in period of 12 weeks, when the insulin
dose was titrated to a target SMPG level of 160 mg/dL,
(a) Baseline iGlarLixi (b) Week 26 (LOCF) iGlarLixi












Figure 1 | Proportion of patients in each glycemic category at baseline and week 26 among patients treated with (a) and (b) fixed-ratio
combination of insulin glargine and lixisenatide (iGlarLixi) or (c) and (d) insulin glargine 100 U/mL (iGlar). Data are the proportions of all patients in
the modified intent-to-treat population in the overall study population. Week 26 data are based on last observation carried forward (LOCF).
Hyperglycemia is defined as glycated hemoglobin (HbA1c) ≥7% and fasting plasma glucose (FPG) ≥130 mg/dL; residual hyperglycemia is defined
as HbA1c ≥7% and FPG <130 mg/dL; and HbA1c at target is defined as HbA1c <7% and FPG <130 mg/dL or ≥130 mg/dL.
Table 1 | Baseline demographics and disease characteristics of patients with residual hyperglycemia at baseline
Characteristic iGlarLixi (n = 83) iGlar (n = 79)
Age, years 60.4 (9.9) 59.9 (10.9)
Duration of diabetes, years 12.70 (8.21) 12.93 (7.47)
Body weight, kg 61.65 (12.05) 63.39 (15.03)
BMI, kg/m2 23.49 (3.47) 23.78 (4.13)
HbA1c, % 8.22 (0.53) 8.20 (0.48)
FPG, mg/dL 108.11 (14.90) 109.32 (14.93)
2-h PPG, mg/dL 254.27 (53.34) 260.63 (62.37)
Duration of diabetes, years 12.70 (8.21) 12.93 (7.47)
Duration of prior basal insulin treatment, years 2.44 (1.77) 2.87 (2.92)
Average daily dose of iGlar, U† 11.73 (2.80) 11.20 (3.15)
OAD use at screening, n (%)
Metformin 69 (83.1) 56 (70.9)
Other‡ 46 (55.4) 44 (55.7)
Data are mean (standard deviation) at baseline for the modified intent-to-treat population, unless otherwise stated. †Averaged daily dose for the
3 days before randomization. ‡Other classes were as follows: alpha-glucosidase inhibitor, sodium glucose co-transporter 2 inhibitor, sulfonylurea, glin-
ide, and dipeptidyl peptidase-4 inhibitor. BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; iGlar, insulin glargine
100 U/mL; iGlarLixi, fixed-ratio combination of insulin glargine and lixisenatide; OAD, oral antidiabetic drug; PPG, postprandial plasma glucose.
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approximately one-third of patients had baseline residual hyper-
glycemia. At week 26 (LOCF), treatment with iGlarLixi reduced
this proportion of patients by more than half to 15.7%, whereas
the proportion of patients with residual hyperglycemia in the
iGlar group increased to 36.9%. The iGlarLixi treatment
resulted in a higher proportion of patients with residual hyper-
glycemia at baseline attaining HbA1c <7% at week 26 when
compared with iGlar treatment, with greater mean reductions
in HbA1c. These findings add to the data from the LixiLan JP-
L trial and increase our understanding of the treatment of Japa-
nese patients with type 2 diabetes who experience residual
hyperglycemia. In the iGlar group, the proportion of patients
with residual hyperglycemia increased at week 8 and remained
higher than in the iGlarLixi group through to the end of treat-
ment (Figure 2); this suggests that the lack of effect on PPG










Baseline Week 4 Week 8 Week 12 Week 16 Week 20 Week 26 Week 26
(LOCF)
Number 257255
1.81% 3.29% –9.02% –13.08% –22.77% –22.14% –23.51% –21.11%
–6.25, 9.87 –4.90, 11.48 –17.60, –0.43 –21.54, –4.62 –30.81, –14.73 –29.90, –14.37 –31.29, –15.73 –28.54, –13.69










































Figure 2 | Proportion of patients with residual hyperglycemia over time. CI, confidence interval; iGlar, insulin glargine; iGlarLixi, fixed-ratio
combination of insulin glargine and lixisenatide; LOCF, last observation carried forward.
Table 2 | Status of patients by glycemic control categories at week 26 (LOCF) according to baseline category
Status iGlarLixi (n = 255) iGlar (n = 257)
Baseline hyperglycemia, n (%) 172 (67.5) 178 (69.3)
Of whom status at week 26 (LOCF), n (%)
Hyperglycemia 60 (34.9) 99 (55.6)
Residual hyperglycemia 25 (14.5) 52 (29.2)
HbA1c at target 87 (50.6) 25 (14.1)
Missing 0 2 (1.1)
Baseline residual hyperglycemia, n (%) 83 (32.5) 79 (30.7)
Of whom status at week 26 (LOCF), n (%)
Hyperglycemia 22 (26.5) 21 (26.6)
Residual hyperglycemia 15 (18.1) 42 (53.2)
HbA1c at target 45 (54.2) 16 (20.3)
Missing 1 (1.2) 0
Data are from the modified intent-to-treat population. HbA1c, glycated hemoglobin; iGlar, insulin glargine 100 U/mL; iGlarLixi, fixed-ratio combina-
tion of insulin glargine and lixisenatide; LOCF, last observation carried forward.
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differential effect between basal glucose and PPG, which
increases the number of patients with residual hyperglycemia
when treated with iGlar alone. These effects were demonstrated
despite there being no differences in the increase in insulin
dose over 26 weeks between the treatments, and despite com-
parable numbers of documented symptomatic hypoglycemic
episodes. The incidence of treatment-emergent adverse events
(TEAEs) in the overall population was similar in the iGlarLixi
and iGlar arms (61.2 and 58.0%, respectively)27; a summary of
TEAEs has been provided in Table S1. The proportion of
patients with documented symptomatic hypoglycemia in the
current analysis (plasma glucose ≤70 mg/dL) was 22.9% with
iGlarLixi and 25.3% with iGlar compared with 18.8% with
iGlarLixi and 16.7% with iGlar in the overall population
(plasma glucose ≤70 mg/dL)27.
The control of postprandial hyperglycemia is a major unmet
need for patients with type 2 diabetes and is a limiting factor
in the long-term success of insulin-based therapies31. High
Table 3 | Changes in weight, glucose parameters, and insulin dose from baseline to week 26 in patients with residual hyperglycemia at baseline
Parameter iGlarLixi (n = 83) iGlar (n = 79) LS mean difference
(SE) (95% CI)
P-value
Body weight (kg, mean [SD])
Baseline 61.61 (12.11) 63.39 (15.03)
Week 26 (LOCF) 61.21 (12.47) 63.96 (15.28)
Change -0.40 (2.17) 0.57 (1.69) -0.97 (0.317)
(-1.600, -0.347)
P = 0.0025
HbA1c (%, mean [SD])
Baseline 8.22 (0.53) 8.20 (0.48)
Week 26 (LOCF) 7.05 (0.87) 7.75 (0.84)
Change -1.17 (0.87) -0.44 (0.73) -0.72 (0.128)
(-0.967, -0.463)
P < 0.0001
FPG (mg/dL, mean [SD])†
Baseline 108.04 (14.98) 109.32 (14.93)
Week 26 (LOCF) 122.96 (38.74) 115.67 (28.12)
Change 14.93 (41.92) 6.35 (30.46) 7.33 (5.485)
(-3.504, 18.164)
P = 0.1834
2-h PPG (mg/dL, mean [SD])‡
Baseline 252.80 (51.16) 256.86 (61.85)
Week 26 (LOCF) 141.61 (55.92) 233.32 (61.55)
Change -111.19 (71.34) -23.54 (55.32) -90.65 (9.110)
(-108.654, -72.646)
P < 0.0001
Average daily dose of iGlar (U, mean [SD])
Baseline 11.73 (2.80) 11.20 (3.15)
Week 26 (LOCF) 15.59 (4.03) 15.67 (4.49)
Change 3.85 (3.88) 4.47 (3.08) -0.51 (0.565)
(-1.629, 0.601)
P = 0.3640
Patients with documented symptomatic
hypoglycemia§ (≤70 mg/dL), n (%)
19 (22.9) 20 (25.3) Proportional difference (95% CI): -4.68%
(-18.31, 8.95)
P = 0.4995
Data are from the modified intent-to-treat population. The difference is calculated as values for iGlarLixi minus values for iGlar. Patients with both
baseline and week 26 (LOCF) measurements are included in the analysis. †n = 82 patients in the iGlarLixi group. ‡n = 79 patients in the iGlarLixi
group and n = 72 patients in the iGlar group. §Hypoglycemia occurring during the period defined as the time from the first injection of open-
label study drug up to 1 day after the last injection of open-label study drug, regardless of the introduction of rescue therapy. CI, confidence inter-
val; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; iGlar, insulin glargine 100 U/mL; iGlarLixi, fixed-ratio combination of insulin glargine
and lixisenatide; LOCF, last observation carried forward; LS, least squares; PPG, postprandial plasma glucose; SD, standard deviation; SE, standard
error.
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baseline rates of residual hyperglycemia in patients entering the
LixiLan JP-L trial underscore the need for a therapeutic strategy
that targets both FPG and PPG in Japanese patients. This ther-
apeutic need is also evidenced by the high rate of residual
hyperglycemia observed at the endpoint of randomized con-
trolled trials of basal insulin worldwide, with rates exceeding
40% in a review of Asia-Pacific trials9.
The effect of the FRC iGlarLixi in reducing the rate of
residual hyperglycemia observed in this post-hoc analysis is
consistent with the complementary mechanism of action of
the GLP-1 RA Lixi and basal insulin32–34. Although Lixi
improves glycemic control irrespective of b-cell function, the
proportion of patients with type 2 diabetes and reduced b-cell
function reaching HbA1c <7% was low despite a substantial
reduction in PPG, suggesting the importance of combining
Lixi with basal insulin in some populations32,33,35. Combining
the GLP-1 RA Lixi with basal insulin provides benefits, as
demonstrated in the present analysis by the improvement in
residual hyperglycemia observed with iGlarLixi compared with
iGlar, despite both iGlar and iGlarLixi having the same dose
of insulin (Table 3). Among patients with residual hyper-
glycemia at baseline, the mean HbA1c at week 26 was 7.05%
with iGlarLixi and 7.75% with iGlar, while the average daily
dose of iGlar at week 26 was 15.59 U with iGlarLixi and
15.67 U with iGlar. This demonstrates the significant contri-
bution of the GLP-1 RA Lixi in improving HbA1c by con-
trolling PPG in patients with residual hyperglycemia, as
indicated by their 7-point SMPG profiles.
The benefits of iGlarLixi in reducing the rates of residual
hyperglycemia have previously been demonstrated for non-
Japanese patients in a post-hoc analysis of the LixiLan-L
trial36,37. That study used formulations of iGlarLixi containing
iGlar to Lixi ratios of 2 U:1 lg and 3 U:1 lg. The data pre-
sented here confirm the effect of iGlarLixi on residual hyper-
glycemia in Japanese patients with type 2 diabetes using a Lixi:
insulin ratio of 1:1, in keeping with the lower typical insulin
requirements in this population.
Similar effects on residual hyperglycemia have been described
in both the USA and EU using iGlarLixi formulations at 2:1
and 3:136–39. This substudy confirms that the 1:1 unique formu-
lation available in Japan delivers similar therapeutic benefits at
lower insulin doses that are commonly seen in real-world prac-
tice40.
In this analysis, patients with residual hyperglycemia at base-
line had a numerically lower BMI than the overall study popu-
lation. In a Caucasian population a lower BMI would
theoretically indicate a population more responsive to insulin.
However, this relationship is not evident in Japanese patients,
in whom type 2 diabetes is frequently observed in patients
without obesity41. The BMI was identical between the treatment
groups in this analysis, indicating that the greater glycemic ben-
efits of FRC therapy vs insulin were not due to baseline differ-
ences in potential responsiveness. Furthermore, the treatment
effect of iGlarLixi was not dependent on BMI in previous
investigations; in a subgroup analysis of the LixiLan-O trial, the
glycemic effect of iGlarLixi was not affected by BMI42. In this
trial of insulin-naive patients with type 2 diabetes, iGlarLixi led
to greater reductions in HbA1c and a higher proportion of
patients achieving HbA1c <7% at week 30, when compared
with iGlar or Lixi given alone irrespective of a baseline BMI
<30 kg/m2 or ≥30 mg/m2 42.
It is known that glycemic fluctuations lead to the deteriora-
tion of pancreatic b-cell function (such as reduced insulin
secretory capacity) in Japanese patients, whose b-cells are more
vulnerable to hyperglycemia compared with those of Cau-
casians43–45. Glucose fluctuations have been reported to induce
excessive formation of reactive oxygen species, inflammatory
cytokines, and oxidative stress, contributing to the apoptosis of
b-cells46. In addition, the fact that glycemic fluctuations may
lead to the development of atherosclerosis and subsequent,
potentially serious cardiovascular conditions has drawn much
attention47,48. Therefore, it is possible that substantially reducing
residual hyperglycemia using iGlarLixi would have additional
beneficial effects in the face of the deterioration of b-cell func-
tion and the development of atherosclerosis in the long term,
particularly in Japanese patients with type 2 diabetes. Needless
to say, further study with a much larger population would be
necessary to address this point.
It is important to note several limitations of the current
analyses. Post-hoc analyses and sub-analyses are inherently
entirely dependent on the design of the primary trial. There-
fore, the sample size and power calculation for the primary
endpoint may not have been applicable to these analyses, par-
ticularly as patient numbers were considerably reduced in the
subgroups. For these reasons, P values should be considered
nominal. Additionally, some outcomes of LixiLan JP-L may
potentially have been influenced by the trial’s open-label
design, which was necessitated by distinctly different adminis-
tration devices. Although not related to these sub-analyses, it
is also important to note that the LixiLan JP trials had a rela-
tively short duration (26 weeks; the JP-O1 trial had an exten-
sion to 52 weeks for safety follow-up), and studies with
longer treatment/follow-up periods are needed to assess long-
term efficacy and safety. As with all clinical trials and associ-
ated post-hoc analyses, real-world studies are needed to con-
firm the findings of the current analyses.
In conclusion, in this post-hoc analysis of the LixiLan JP-L
trial, a titratable 1:1 FRC of iGlarLixi was more effective than
iGlar in reducing the overall rate of residual hyperglycemia in
Japanese patients with type 2 diabetes over 26 weeks, and it
was also more effective in reducing HbA1c in those patients
with residual hyperglycemia.
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